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Abstract:  Vitamin E consists of eight different variants: α-,  β-,  γ-, and δ-tocopherols 
(saturated phytyl tail) and α-, β-, γ-, and δ-tocotrienols (unsaturated phytyl tail). Cancer 
prevention studies with vitamin E have primarily utilized the variant α-tocopherol. To no 
avail, a majority of these studies focused on variant α-tocopherol with inconsistent results. 
However,  γ-tocopherol, and more recently δ-tocopherol, have shown greater ability to 
reduce inflammation, cell proliferation, and tumor burden. Recent results have shown that 
γ-enriched mixed tocopherols inhibit the development of mammary hyperplasia and 
tumorigenesis in animal models. In this review, we discuss the possible differences 
between the variant forms, molecular targets, and cancer-preventive effects of tocopherols. 
We recommend that a γ-enriched mixture, γ- and δ-tocopherol, but not α-tocopherol, are 
promising agents for breast cancer prevention and warrant further investigation.  
Keywords: vitamin E; tocopherols; breast cancer;  estrogen receptor (ER); peroxisome 
proliferator activated receptor γ (PPARγ); nuclear factor (erythroid-derived 2)-like 2 
(Nrf2); anti-inflammatory; cell proliferation; apoptosis; case-control studies 
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1. Tocopherols 
Due to its antioxidant properties, dietary intake of vitamin E, a fat-soluble vitamin, has been 
suggested to reduce cancer risk [1]. Vitamin E consists of eight different forms which include four 
tocopherols (with a saturated phytyl tail) and four tocotrienols (with an unsaturated isoprenoid side 
chain), designated as α, β, γ, and δ variants (Figure 1) [2].  
Figure 1. Chemical structures of α-, β-, γ-, and δ-tocopherols.  
 
α-Tocopherol is known as the “classic” vitamin E, because of its superior activity over the other 
tocopherols in the classic fertility restoration assay [3]. α-Tocopherol is most commonly found in 
wheat germ, almond, and sunflower oil [4]. However, γ-tocopherol is more prominent than α-tocopherol 
in the American diet and is found in vegetable oils such as soybean, corn, and cottonseed [5].   
δ-Tocopherol is primarily found in soybean and castor oils, and to a lesser extent, in wheat germ oil [6]. 
A tocopherol mixture containing 58% γ-tocopherol, 24% δ-tocopherol, 13% α-tocopherol, and 0.5%  
β-tocopherol (γ-TmT) can be easily available as a by-product of refining vegetable oil [7,8]. 
Tocotrienols are consumed more readily in East-South Asian diets, and found primarily in palm and 
annatto oils [9,10]. Since tocopherols are the main components of vitamin E in the American diet, this 
review will focus on tocopherols. The first non antioxidant function of vitamin E determined that  
α-tocopherol inhibited the activity of smooth muscle proliferation and protein kinase C [11,12]. Since 
then, three proteins have been identified to specifically bind to tocopherols: α-tocopherol transfer 
protein (α-TTP), tocopherol-associated protein (TAP), and tocopherol-binding protein (TBP). α-TTP is 
a 30–35 kDa protein and found in the liver [13] which preferentially transfers α-tocopherol from the 
liver to the blood [14]. The relative affinities of α-TTP for the variants of vitamin E as determined 
in vitro were 100% for α-tocopherol, 38% for β-tocopherol, 9% for γ-tocopherol, 2% for δ-tocopherol, 
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and 12% for α-tocotrienol [15]. Thus, the major tocopherol found in human blood and tissues is   
α-tocopherol [3]. Similar to α-TTP, TAP is also a cystolic lipid-binding and transfer protein. TAP is a 
46-kDa protein and has the highest levels in the liver > prostate > whole brain > spinal cord > kidney > 
mammary gland > stomach [16]. TBP was initially found in rat liver and heart is an approximately  
15 kDa cystolic protein [17] and later in human placenta [18]. TBP is involved in intracellular 
transport and metabolism for α-tocopherol [19].  
In the liver, vitamin E is metabolized to chromanol metabolites via the hepatic protein, cytochrome 
P450 4F2. CYP4F2 catalyzes the initial step in the vitamin E-ω-hydroxylase pathway followed by  
β-oxidation, which removes 2 carbons from the side chain in each cycle ending in the short chain 
metabolite, carboxyethyl hydroxychromans (CEHC) [14,20]. Since α-tocopherol is preferentially 
transferred to the blood by α-TTP, γ-tocopherol and δ-tocopherol are more readily metabolized in the 
liver [14].  
Interestingly, higher concentrations of α-tocopherol may decrease the level of γ-tocopherol in the 
serum [21,22]. This may be unfavorable since γ-tocopherol has demonstrated significantly greater   
anti-inflammatory and anti-tumor activity than α-tocopherol in several different animal models of 
colon, breast, and prostate cancer [22–27]. More specifically, γ-tocopherol is more effective in 
inhibiting the activity of cyclooxygenase-2 (COX-2) [23,28] and trapping reactive nitrogen species 
than α-tocopherol [23,28–32].  
The stability of tocopherol and nitrogen species derivative depends on the structure of the chromanol 
ring [32]. The tocopherols with a free 5 position on the chromanol ring (γ- and δ-tocopherol) are 
expected to react with nitrogen species forming C-nitroso derivatives at this position [32]. Both   
α-tocopherol and γ-tocopherol react with nitrogen dioxide NO2; α-tocopherol forms an intermediate 
tocopheroxide analogue while γ-tocopherol may form nitric oxide (NO) or a stable nitro derivative  
(5-nitro-γT) [32]. α-Tocopherol is trimethylated, and consequently, the nitrosating agent only has the 
possibility to add to the para-position on the chromanol ring of α-tocopherol, forming a highly 
unstable compound and may form toxic N-nitroso-derivatives from amines [32]. In addition, α-tocopherol 
may react with nitrous acid to yield α-tocopherol quinone and nitrogen monoxide gas [33]. This may 
lead to highly instable derivatives which may act as nitrosation catalysts for secondary amines.   
The high hydrogen donation ability by α-tocopherol may cause undesirable side effects, such as   
pro-oxidant and toxic nitro derivatives [34].  
Tocopherols are recognized for their inhibition of lipid oxidation [35]. The antioxidant properties 
are mostly due to the phenolic hydrogens in the chromanol ring that are donated to lipid free   
radicals [36]. α-Tocopherol is trimethylated at the 5-, 7-, and 8-positions on the chromanol ring,   
γ-tocopherol is dimethylated at 7- and 8-positions, and δ-tocopherol is monomethylated at the   
8-postion on the chromanol ring. The structural difference in the chromanol ring may be responsible 
for the difference in activity of each individual tocopherol form. The ortho-positions (positions 5 and 7) 
for the methyl groups on the chromanol ring enhance the antioxidant properties of tocopherols and 
increases the solubility in lipid substrates [33]. Thus, α-tocopherol with two ortho-methyl groups is 
expected to be a more potent hydrogen donor than either γ-tocopherol (one ortho methyl group) and  
δ-tocopherol (zero ortho methyl group) [33]. Although α-tocopherol may be a better antioxidant,   
α-tocopherol consequently has a greater capacity than γ-tocopherol and δ-tocopherol to act as a Nutrients 2011, 3  
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prooxidant when present in high concentrations in vegetable oils, and with transition metal ions, lipid 
peroxides, and other oxidizing agents [33,34]. 
α-Tocopherol has been the most widely studied form of vitamin E for the prevention and treatment 
of cancer [37–40]. Although the biological effects of α-tocopherol have been investigated over many 
decades, our current understanding of its role in inhibiting breast carcinogenesis remains incomplete [41]. 
The structural difference of the individual tocopherols plays a role in the variance of antioxidant 
properties, lipophilicity, and the ability to trap reactive nitrogen species (RNS). Both γ- and δ-tocopherol, 
but not α-tocopherol, show promise as chemopreventive agents in animal models [7,42,43]. In addition,  
γ-TmT is a mixture of tocopherols enriched with γ-tocopherol and is readily available and inexpensive, 
while individual variants remain expensive to purify. As a result, γ-TmT may be more practical rather 
than individual tocopherols for the prevention of breast cancer.  
2. Subtypes of Breast Cancer 
Breast cancer is one of the most common malignancies affecting women and is the second leading 
cause of cancer death in women [44]. The etiology and pathogenesis of breast cancer remains poorly 
understood. Breast cancer is a heterogeneous disease that can be classified into subtypes based on 
immunohistochemical markers. The subtypes are: estrogen receptor (ER) positive luminal A, ER positive 
luminal B, human epidermal growth factor receptor-2 positive (HER2 positive), and basal-like [45].  
2.1. Estrogen Receptor (ER) Positive  
Estrogen receptor positive tumors are classified as a luminal subtype of breast cancer and are 
reported in 60–70% of cases [45]. Luminal tumors activate ER-responsive genes, other genes that 
encode characteristic proteins of luminal epithelial cells of origin, and express luminal cytokeratin  
8/18 [45]. Luminal A subtype is either ER positive or progesterone receptor (PR) positive but is 
negative for HER2. Luminal B subtype can be classified as ER positive or PR positive and is positive 
for HER2 [46]. The prognosis for luminal A is better than luminal B and typically responds more 
effectively to selective estrogen receptor modulators, such as tamoxifen [45]. 
Estrogens have been implicated in breast cancer; however, the mechanism of action still remains 
unclear. One theory suggests that the mechanism is dependent on the activation of the ER. Estrogen 
induces breast cancer through stimulation of cellular proliferation, resulting in more opportunities for 
accumulation of genetic damages leading to carcinogenesis [47]. Another possible mechanism of 
action may be through the metabolism of estrogen, which may induce oxidative stress and play a key 
role in mammary cancer development [48,49]. 17β-Estradiol and estrone are continuously interconverted 
by 17β-estradiol hydroxysteroid dehydrogenase (or 17β-oxidoreductase) and are the two major 
endogenous estrogens. The carbon position of the estrogen molecules that are hydroxylated differs 
among various tissues in the body and each reaction is probably catalyzed by various CYP enzymes. 
For example, estrogen may be metabolized by CYP 1A1 to form 2-hydroxyestradiol (2-OHE2) or by 
CYP 1B1 to form 4-hydroxyestradiol (4-OHE2). These catechols may be methylated by a phase II 
enzyme, catechol o-methyltransferase (COMT), and excreted out of the body [50]. The 2-OHE2 
metabolite is rapidly methylated by COMT, while the 4-OHE2 metabolite is methylated more slowly 
and thus highly genotoxic [49]. If catechol estrogens are not conjugated (mostly 4-OHE2), it may lead Nutrients 2011, 3  
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to the formation of semiquinones and subsequently quinones, both of which are electrophiles capable 
of covalently binding to nucleophilic groups on DNA which may form DNA-adducts [47]. The 
protective phase II enzyme, NAD(P)H dehydrogenase, quinone 1 (NQO1), catalyzes the reduction of 
quinones back to catechol estrogens [51].  
Under normal conditions, reactive oxygen species (ROS) or RNS are neutralized by detoxifying and 
antioxidant enzymes [43]. Oxidative stress and/or electrophilic stress during redox cycling of catechol 
estrogens could contribute to nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activation. The estrogen 
metabolites, 4-OHE1, 4-OHE2, and 2-OHE2 were capable of activating Nrf2, while estradiol did   
not [52]. This suggests that a catechol structure is required for activation of Nrf2. Estrogen metabolites 
may exert DNA mutations from ROS or DNA mutations which may lead to the accumulation of 
genomic alterations essential for mammary tumorigenesis [47]. In one study, 49 women without breast 
cancer were observed with larger amounts of 2-OHE2 than 4-OHE2 [53]. The 28 women with breast 
carcinoma expressed 4-OHE2 levels that were 3.5 times more abundant than 2-OHE2 [53]. This 
supports the finding that estrogen and its metabolites, mainly 4-OHE2, may be carcinogenic agents in 
breast epithelial cells [53].  
2.2. Human Epidermal Growth Factor Receptor 2 (HER2) 
HER2 amplification and overexpression has been reported in 18–25% of human breast cancers [54]. 
HER2 positive breast cancer can be characterized as HER2 positive, negative for ER, and poor 
differentiation [55]. The prognosis for HER2 positive is worse than luminal breast cancer. HER2 
positive breast cancer may be treated with monoclonal antibodies such as trastuzumab (binds to 
domain IV on the HER2 receptor); however, there are HER2 positive tumors that are resistant to 
trastuzumab treatment [55]. Other treatments include monoclonal antibody pertuzumab (binds to 
domain II of the HER2 receptor) [56], trastuzumab antibody conjugated with mertansine (DM1), 
which is internalized and exerts its cytotoxic effects inside the cell [57], tyrosine kinase inhibitors [58], 
and HSP90 inhibition which leads to proteasomal degradation [59].  
HER2 is a member of the epidermal growth factor (ErbB) family of transmembrane receptors which 
are potent mediators of normal cell growth and development [60]. The ErbB family is classified as a 
tyrosine kinase receptor and consists of EGFR (HER1), ERBB2 (HER2), ERBB3 (HER3), and ERBB4 
(HER4). The structure consists of an extracellular domain at which the ligand binding occurs, the  
α-helical transmembrane segment, and the intracellular protein tyrosine kinase domain [61]. ErbB 
receptors normally exist as inactive monomers until a ligand initiates a conformational change to 
induce dimerization with another receptor. HER2 is unique in the fact that it already possesses an active 
tyrosine kinase domain and has no direct ligand while HER3 lacks an intrinsic tyrosine kinase activity 
and cannot form homodimers with itself [62]. The HER2-HER3 heterodimer is considered the most 
potent and active ErbB dimer [63–65]. HER2 signaling leads to oncogenic cell survival and proliferation 
through the MAPK pathway [66]. HER3 can directly bind to the p85 subunit of PI3K to stimulate the 
PI3K-Akt pathway while EGFR and HER2 have additional activation steps by binding to the adaptor 
proteins GRB2 (growth factor receptor bound 2) and GAB1 (GRB2-associated binding protein 1) [67]. 
Thus, the HER2-HER3 dimer leads to the MAPK pathway to stimulate angiogenesis, proliferation, and 
PI3K-Akt pathway to promote cell survival, suppression of apoptosis, and cell cycle control [66].  Nutrients 2011, 3  
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2.3. Basal-Like 
Basal-like subtype is characterized by ER and HER2 negativity, high expression of basal stratified 
epithelial cytokeratins 5, 6, and 17, and expression of proliferation-related genes [45,68]. The 
prognosis of basal-like tumors is poor, with frequent mutations in TP53 [69]. BRCA1 mutations are 
also generally basal-like breast tumors [68,69]. The incidence of basal-like breast cancer may be 
increased by both race and age, where premenopausal African American women developed basal-like 
tumors (39%) compared to postmenopausal African American women (14%) and non-African American 
women (16%) [70]. In addition, microarray analysis revealed that younger patients of any ethnicity 
tend to form basal-like tumors over other types [69,70].  
3. Cellular Events and Molecular Targets in Breast Cancer  
Each subtype of breast cancer responds differently to current treatments and therapy. To date, there 
is limited in vitro, in vivo, and human data which connect individual tocopherols for prevention or 
treatment for each subtype of breast cancer. Chemoprevention is an approach to prevent cancer before 
a series of genetic and epigenetic events establish which otherwise could lead to malignancies. Thus, 
prevention of breast cancer is essential, and the success of prevention strategies depends on 
understanding the molecular mechanism of breast cancer initiation and progression. The mechanisms 
of anti-cancer activity of tocopherols have been investigated for many years [39,71,72] and can be 
summarized as follows: (a) inhibition of ER (b) increasing peroxisome proliferator activated receptor γ 
(PPARγ) expression and activity, (c) induction of Nrf2, (d) antioxidative and anti-inflammatory 
activities, and (e) induction of apoptosis [28,39,43,72,73].  
3.1. Estrogen Receptor (ER) 
ER is a nuclear receptor that stimulates cell growth and proliferation [48]. The ER is a ligand-activated 
transcription factor that, when bound to estrogen, induces a conformational change that allows 
dimerization and binding to estrogen response element sequences. There are two known ER receptors: 
ERα and ERβ. The DNA binding domain of the two different receptors is highly homologous while the 
ligand binding domain is 60% homologous [74]. ERα and ERβ are both present in breast tissue, but the 
ratio of ERα to ERβ is increased in breast tumors [74]. The role of ERβ in breast tumorigenesis is not 
well understood. Some studies have shown that activation of ERβ in breast cancer cell lines inhibits 
cell growth, and the dimerization of ERβ with ERα silences the growth-promoting effects of ERα [74,75].  
Vitamin E has been shown to inhibit ER-positive cell proliferation and work as antagonists of 
estrogen signaling in MCF-7 and T47D breast cancer cells [73]. MCF-7 cells were treated with γ-TmT, 
and the expression of ERα was down-regulated [7]. In mammary tumors, ERα mRNA and protein 
levels were down-regulated by the treatment of γ-TmT [7]. Administration of γ-TmT reduced ERα 
mRNA and protein levels in hyperplastic mammary tissues in estrogen-treated ACI rats, while mRNA 
levels of ERβ were increased [76]. Furthermore, dietary γ-TmT decreased circulating levels of E2 in 
the serum, suggesting that γ-TmT may modify the response to estrogen [76].  
  Nutrients 2011, 3  
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3.2. Peroxisome Proliferator Activated Receptor γ (PPARγ) 
Belonging to the nuclear hormone receptor superfamily, PPAR comprises of 3 subtypes (α, γ, and δ) 
which are ligand-regulated transcription factors [77]. PPARγ is known to be involved in fatty acid 
uptake and transport and acts to control inflammation by inducing apoptosis and inhibiting cell 
proliferation cell survival [78,79]. PPARγ signaling is connected to the inhibition of inflammatory 
markers (COX-2, cytokines, and inducible nitric oxide synthase), PI3K/Akt pathway, and angiogenesis 
while inducing CDK inhibitors, differentiation and apoptosis markers in cancers [79]. Particularly in 
breast cancer, stimulation of PPARγ increases the degradation of cell cycle genes (Cyclin D1), 
interferes with estrogen receptor signaling, and NF-κB signaling cascades [80,81].  
When ligand-activated, PPARγ forms a heterodimer with the retinoid X receptor [78]. A known 
PPARγ ligand is troglitazone [27], and the chromanol ring of tocopherol is structurally similar. 
Recently it was thought that tocopherols might function as a PPARγ ligand because of this structural 
resemblance, but it was shown that γ-tocopherol does not directly bind to PPARγ [81]. Instead,   
γ-tocopherol induces the formation of 15-S-hydroxyeicosatetraenoic  acid, an endogenous PPARγ 
ligand [81].  
Tocopherols, with γ-tocopherol displaying the strongest activity, increased mRNA and protein 
levels of PPARγ in colon cancer cells [27] and transcriptional activity in keratinocytes cell line [82] 
(Table 1). In MCF-7 and T47D breast cancer cells, γ-TmT, γ-tocopherol, and more strongly δ-tocopherol 
enhance the transactivation of PPARγ [7]. Comparable to the finding in the N-methyl-N-nitrosourea 
(NMU)-induced breast cancer model in Sprague-Dawley rats [7], PPARγ was increased at both the 
protein and mRNA level in the mammary gland of ACI rats when treated with γ-TmT while ERα 
expression was decreased [76]. Since PPARγ transactivation can be suppressed by ERα binding to the 
PPAR response element [83], the inhibition of ERα expression by tocopherols may result in the 
activation of PPARγ. Thus, tocopherols may indirectly activate PPARγ, and possibly through this 
pathway may interfere with ERα expression, inhibit cell cycle progression and induce apoptosis to 
prevent breast cancer.  
Table 1. Tocopherols induce PPARγ levels. 
Tocopherol Cell  type/Cancer  model  Result  References
γ-Tocopherol  Colon cancer cells (SW 480)  ↑ PPARγ mRNA and protein level  [27] 
γ-Tocopherol  Keratinocytes cells (NCTC 2544)  ↑ PPARγ mRNA levels  [82] 
γ-TmT,  
γ-Tocopherol, 
δ-Tocopherol 
Breast cancer cells (MCF-7 and T47D)  ↑ PPARγ transactivation  [7] 
γ-TmT 
NMU-induced mammary tumors in 
female Sprague-Dawley rats 
↑ PPARγ mRNA and protein level  [7] 
γ-TmT 
Estrogen-induced mammary 
hyperplasia in female ACI rats 
↑ PPARγ mRNA and protein level  [76] 
3.3. Nuclear Factor (Erythroid-Derived 2)-Like 2 (Nrf2) 
Nrf2 is a transcription factor that is a key regulator of cellular antioxidant and detoxification 
enzymes [84]. Initially, Nrf2 activity is inhibited when bound to kelch-like-ECH-associated protein 1 Nutrients 2011, 3  
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(KEAP1) in the cytoplasm and is marked for degradation through the proteasomal pathway [84]. 
Under oxidative stress or chemopreventive agents, KEAP1 undergoes covalent modification which 
allows the release and the consequential activation of Nrf2 [84–86]. As a result, Nrf2 translocates into 
the nucleus, dimerizes with small Maf proteins, and binds to the antioxidant-responsive element (ARE) 
to stimulate gene expression of antioxidant enzymes (thioredoxin, superoxide dismutase[SOD], catalase, 
glutathione peroxidase, and heme oxygenase-1[HO-1]), and phase II detoxification enzymes (glutathione 
s-transferases[GST], UDP-glucuronosyltransferases, sulfotransferases, and NQO1) [43,84–87]. As a 
result, these detoxifying and antioxidant enzymes protect cells from neoplastic transformation by 
maintaining oxidative stress homeostasis [43,88]. A loss of Nrf2 may lead to a decrease in cellular 
defense against oxidative stress which may result in tumorigenesis [89].  
In human retinal pigment epithelial cells, pretreatment with α-tocopherol inhibited ROS generation, 
increased Nrf2 expression, and, induced phase II enzymes (glutamate cysteine ligase, NQO1, HO-1, 
GST, and SOD) [90] (Table 2). The expression of Nrf2 was suppressed in prostate tumors [91], and 
treatment with γ-TmT upregulated the expression of Nrf2 and detoxifying enzymes, and inhibited 
tumor development in TRAMP mice [43,91]. We recently demonstrated that when estrogen-treated 
ACI rats were administered γ-TmT diet, the protein expression level of Nrf2 was increased in the 
mammary gland and liver, and phase II enzymes were increased in the liver [92]. The mRNA 
expressions of phase II detoxifying enzymes were induced in the mammary gland and liver by γ-TmT 
treatment. This may indicate that γ-TmT induces the transcription of Nrf2-ARE-target genes and 
exhibits protective defense against estrogen induced oxidative stress.  
Table 2. Tocopherols induce Nrf2 and related antioxidant enzymes. 
Tocopherol Cell  type/Cancer  model  Result  References 
α-Tocopherol 
Human retinal pigment 
epithelial cells (ARPE-19) 
↑ Nrf2 protein levels, ↑ glutamate 
cysteine ligase, NQO1, HO-1, GST, SOD 
[90] 
γ-TmT 
Prostate carcinogenesis in 
TRAMP male mice 
↑ Nrf2 protein levels, ↑ GSTm1, 
UGT1A1, HO-1, catalase, SOD, 
glutathione peroxidase, 
[43] 
γ-TmT 
Estrogen-induced mammary 
hyperplasia in female ACI rats 
↑ Nrf2 protein levels  [92] 
3.4. Cell Proliferation and Apoptosis 
Apoptosis is defined as programmed cell death with distinct morphological and biochemical 
changes [93,94]. During the earlier stages, the apoptotic cell shrinks in volume and the nuclear DNA 
condenses, while the cellular membrane remains intact [94,95]. Apoptotic bodies are formed and the 
tightly packed organelles leave the cell through “budding” [96]. There are two distinct apoptotic 
pathways: extrinsic and intrinsic [97]. Caspases have proteolytic activity and are able to cleave 
proteins. There are ten major caspases with three main sub groups: initiators (−2, −8, −9, and −10), 
effectors (−3, −6, and −7), and inflammatory (−1, −4, and −5) [98,99].  
In breast, colon, lung, and prostate cancer cell lines, γ-tocopherol was shown to be more effective at 
inhibiting cell growth than α-tocopherol [7,25,26,100]. Our in vitro data showed that treatment with  
γ-TmT,  γ-, and δ-tocopherol inhibited cell proliferation in MCF-7 breast cancer cells in a   Nutrients 2011, 3  
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dose-dependent manner, while α-tocopherol did not [7]. In addition, a colony growth inhibition assay 
utilizing MDA-MB-435 breast cancer cells showed that γ- and δ-tocopherol showed potential to inhibit 
colony formation, whereas α-tocopherol was not active [39].  
γ-Tocopherol has been shown to induce apoptosis in breast, colon, and prostate cancer 
cells [26,100–103] (Table 3). Yu et al. showed that apoptosis was induced by δ-tocopherol in MCF-7 
and MDA-MB-435 breast cancer cells [102]. Furthermore, γ-tocopherol, but not α-tocopherol, induced 
cleaved-caspase 8 and 9 in MDA-MB-435 human breast cancer cells [103]. In one xenograft model, 
when treated with γ-tocopherol, tumor growth was inhibited, and TUNEL assay determined that there 
was an increase in apoptotic cells [22]. γ-Tocopherol and to a greater extent, δ-tocopherol, were shown 
to inhibit tumor growth more strongly than α-tocopherol in a lung xenograft model, while α-tocopherol 
did not [42]. 
Table 3. Tocopherols inhibit cell proliferation and induce apoptosis. 
Tocopherol Cell  type/Cancer  model  Result  References 
γ-Tocopherol 
Prostate cancer cells (LNCaP and 
PC-3) and lung cancer cells (A549) 
↓ Proliferation  [101] 
γ-Tocopherol and 
combination of  
γ-Tocopherol and  
δ-Tocopherol 
Prostate cancer cells (LNCaP)  ↑ Apoptosis  [101] 
γ-Tocopherol 
Colon cancer cells (SW480,  
HCT-15, HCT-116, HT-29) 
↓ Proliferation, ↑ Apoptosis  [100] 
γ-Tocopherol  Prostate cancer cells (LNCaP)  ↓ Proliferation, ↑ Apoptosis  [101] 
δ-Tocopherol 
Breast cancer cells (MCF-7  
and MDA-MB-435) 
↑ Apoptosis  [102] 
γ-Tocopherol 
Breast cancer cells (MCF-7 and 
MDA-MB-435) and murine 66cl-4 
↓ Proliferation, ↑ Apoptosis  [103] 
γ-Tocopherol 
Bresat cancer MDA-MB-231 
xenograft in nu/nu mice 
↑ Apoptosis  [22] 
γ-Tocopherol,  
δ-Tocopherol 
Lung cancer H1299 xenograft in 
nu/nu mice 
↑ Apoptosis  [42] 
γ-TmT 
NMU-induced mammary tumors in 
female Sprague-Dawley rats 
↓ Proliferation  [104] 
γ-TmT 
NMU-induced mammary tumors in 
female Sprague-Dawley rats 
↑ Apoptosis  [7] 
γ-Tocopherol,  
δ-Tocopherol,  
γ-TmT 
NMU-induced mammary tumors in 
female Sprague-Dawley rats 
↑ Apoptosis  [105] 
γ-TmT 
Estrogen-induced mammary 
hyperplasia in female ACI rats 
↓ Proliferation, ↑ Apoptosis  [76] 
In vivo models showed that mammary tumor growth and burden was decreased by γ-TmT diet [7,104]. 
Proliferating cell nuclear antigen (PCNA) was decreased in mammary hyperplasia [76] and in 
mammary tumors when administered γ-TmT [104]. Administration of γ-TmT increased the levels of 
cleaved-caspase 3 increased in mammary hyperplasia [76] and in mammary tumors [7]. Furthermore, Nutrients 2011, 3  
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γ-TmT and individual tocopherols were administered to Sprague-Dawley rats which were induced with 
NMU carcinogen; treatment with γ-TmT, γ-, and δ-tocopherol decreased PCNA levels while increased 
the levels of cleaved-caspase 3 in mammary tumors, whereas α-tocopherol was not active [105]. At 
high doses, tocopherols may induce DNA damage leading to apoptosis. There is the possibility of 
tocopherols, especially α-tocopherol, to act as a pro-oxidant to create ROS or RNS. 
3.5. Cyclooxygenase-2 (COX-2) and Anti-Inflammatory Activities  
COX-2 is an inducible prostaglandin synthase which is upregulated by growth factors, tumor 
promoters, and cytokines [106], and responsive to several oncogenes, such as HER2 [107,108].   
In inflamed and neoplastic tissues, an increase in prostaglandin synthesis is detected [107]. Around 
40% of aggressive human breast cancers are associated with high levels of COX-2 which correlates 
with large tumor sizes, high proliferation rates, and metastases [108]. Celecoxib, a COX-2 inhibitor, 
was fed to HER2/neu transgenic mice and found that there was a 50% reduction in mammary 
prostaglandin E2 (PGE2) levels and delayed tumor onset [109].  
Tocopherols are known antioxidants and anti-inflammatory agents, and γ-tocopherol is more 
effective in inhibiting the activity of COX-2 and trapping reactive nitrogen species than α-tocopherol 
(Table 4) [23,28–31,110]. In addition, γ-tocopherol was shown to reduce PGE2 synthesis in 
macrophages and human epithelial cells [28], and the inhibitory effect was due to the decrease of 
COX-2 activity [28,111]. In our study, serum levels of PGE2 and 8-isoprostane, a marker of oxidative 
stress, were reduced when estrogen-induced ACI rats were treated with γ-TmT, and COX-2 levels 
decreased in the mammary gland when treated with dietary γ-TmT [76]. γ-TmT treatment may reduce 
inflammation in an estrogen-induced model of mammary hyperplasia and tumorigenesis.  
Table 4. Tocopherols decrease COX-2 and RNS. 
Tocopherol Cell  type/Cancer  model  Result  References
γ-Tocopherol 
Carrageenan-induced inflammation 
in Wistar male rats 
↓ RNS, ↓ PGE2, ↓ LTB4, ↓ TNF-α [29] 
γ-Tocopherol 
Macrophages (RAW264.7) and 
human epithelial cells (A549) 
↓ COX-2, ↓ PGE2 [28] 
γ-Tocopherol 
Zymosan-induced acute peritonitis 
in male Fischer 344 rats 
↓ RNS  [30] 
γ-Tocopherol Human  plasma  ↓ RNS, ↓ peroxynitrite  [31] 
γ-Tocopherol,  
δ-Tocopherol 
Human epithelial cells (A549)  ↓ COX-2  [111] 
γ-TmT 
Estrogen-induced mammary 
hyperplasia in female ACI rats 
↓ COX-2, ↓ PGE2, ↓ 8-isoprostane  [76] 
4. Studies on Tocopherols and Human Cancers 
4.1. Case-Control and Cohort Studies 
There are several case-control, cohort, and intervention studies on vitamin E and human cancers, 
but our main focus will address breast cancer. Numerous case-control studies utilized vitamin E and Nutrients 2011, 3  
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11 studies found a risk reduction [112–122], however, 13 studies did not find an association with 
breast cancer incidence (Table 5) [123–135]. In the Shanghai Breast Cancer Study, they suggest that 
vitamin E supplement may reduce the risk of breast cancer among women who have low dietary 
intake [122]. To date, 12 cohort studies did not find any relation between vitamin E and prevention of 
breast cancer risk (Table 6) [136–147]. In one cohort study, the European Prospective Investigation 
into Cancer and Nutrition (EPIC) trial observed that vitamin E did not reduce breast cancer risk, but 
there was a weak risk reduction in post-menopausal women [145]. While investigating vitamin 
supplement during breast cancer treatment and survival, Nechuta et al. determined that vitamin E 
supplementation in the first 6 months after diagnosis may reduce risk of mortality and recurrence [148].  
Table 5. Case-control studies of vitamin E and breast cancer risk. 
Study Population  Year  Case/Control 
a  Intake or blood levels 
Relative risk (95% CI) 
for highest vs. lowest level 
Conclusion
[124] Canada 1989–1993 223/85 
Serum or adipose tissue 
levels of α-T: levels were 
not specified 
Serum α-T:  
0.85 (0.45–1.59) 
Adipose tissue α-T: 
1.34 (0.73–2.47) 
No 
association
[125] US 1976–1998
969/969 
 
Serum α-T or γ-T:  
levels were not specified 
Serum α-T: 0.79  
(0.57–1.08) 
Serum γ-T: 0.96  
(0.71–1.30) 
No 
association
[126] US 1975–1994
244/244  
(1974 Study) 
115/115  
(1989 Study) 
Serum α-T:  
0.91–1.40 mg/dL;  
0.99–1.65 mg/dL 
Serum γ-T:  
0.15–0.32 mg/dL;  
0.13–0.34 mg/dL 
Serum α-T: 0.94  
(0.52–1.73);  
0.67 (0.28–1.62) 
Serum γ-T: 0.70  
(0.40–1.23);  
0.80 (0.33–1.93) 
No 
association
[127] US 1975–1993 64/64 
Serum α-T: 1.31 mg/dL 
Serum γ-T: 0.25 mg/dL 
α-T: 0.46 (0.23–0.64) 
γ-T: 0.53 (0.32–0.69) 
No 
association
[113] India   
Pre-M: 28/23 
Post-M: 29/19 
Serum α-T:  
38 vs. 25 μmol/L 
Serum γ-T:  
30 vs. 25 μmol/L 
Serum α-T: P < 0.05 
Serum γ-T: p < 0.02 
Risk 
reduction 
[129] US    27/28 
Serum α-T:  
≤20.5 ~ ≥35 μmol/L 
Serum γ-T:  
≤2.12~ ≥7.573 μmol/L 
Serum α-T:  
0.76 (0.10–5.75) 
Serum γ-T: 
0.31 (0.04–1.93) 
No 
association
[130] Greek   
Pre-M: 270/505 
Post-M: 550/1041
Vit E: <5.2 ~ ≥8.6 IU/day
Pre-M: 0.50 (0.25–1.02) 
Post-M: 0.85 (0.53–1.36) 
No 
association
[114] Finish    Pre-M:  119/324 Vit  E:  ≤7 ~ >13 mg/day  0.5 (0.2–1.0) 
Risk 
reduction 
[115]  Uruguay    400/405  Vit E: 4.7 ~ 9.7 mg/day  0.4 (0.26–0.62) 
Risk 
reduction 
[131] Italian   
Pre-M: 989/841 
Post-M: 1577/1745
Vit E: <8.5 ~ 11.7 mg/day
Pre-M: 1.27 (0.9–1.78) 
Post-M: 1.16 (0.92–1.46) 
No 
associationNutrients 2011, 3  
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Table 5. Cont. 
[132] US 1977–1989 105/203 
Serum α-T:  
≤21.6 ~ ≥31.3 μmol/L 
1.2 (0.5–2.8) 
No 
association
[116] Italy   
Pre-M: 988/843 
Post-M: 1572/1742
Vit E: levels were not 
specified 
Pre-M: 0.8 (0.7–1.0) 
Post-M: 0.75 (0.6–0.9) 
Risk 
reduction
[117] US    297/311  α-T: <6 ~ ≥11 mg/day  0.55 (0.34–0.88) 
Risk 
reduction
[112] US   
Pre-M without 
family history: 
224/251 
α-T: ≤6.3 ~ >10.4 IU/day  0.5 (0.2–1.0) 
Risk 
reduction
[118] US    Post-M:  313/349 
Vit E: 11 vs. 5.4 mg/day 
(median) 
0.4 (0.2–0.9) 
Risk 
reduction
[119] Malaysia    57/139 
Vit E: 6.1 vs. 6.9 mg/day 
(mean) 
2.12 (1.00–4.21) 
Risk 
reduction
[128]  South Korea  2004–2006 362/362  Vit E: 10.6 vs. 11.2 mg/day 0.66 (0.41–1.08) 
No 
association
[120]  Switzerland  1993–1999 289/442  Vit E: 9.4–18.1 mg/day  0.49 (0.35–0.71) 
Risk 
reduction
[121]  Italy  1991–1994 2569/2588  Vit E: 7.21–13.43 mg/day  0.75 (0.6–0.9) 
Risk 
reduction
[123]  Germany  1998–1999 310/353  Vit E: 7.1–12.7 mg/day  1.08 (0.58–2.03) 
No 
association
[122] China 
1996–1998 
and  
2002–2004
3454/3474  Vit E: levels not specified 
Low supplemental Vit E: 
0.7 (0.5–1.0) 
High supplemental Vit E: 
1.2 (0.9–1.6) 
Risk 
reduction
[133] US 1999–2004
1498/1559  
(Non-Hispanic 
white) 763/877 
(Hispanic) 
α-T: 108–224 mg/day 
β-T: 0.3–0.4 mg/day 
γ-T: 15.9–19.4 mg/day 
δ-T: 2.94–3.59 mg/day 
α-T: 0.87 (0.73–1.03) 
β-T: 1.10 (0.89–1.36) 
γ-T: 1.13 (0.89–1.44) 
δ-T: 1.10 (0.89–1.35) 
No 
association
[134] Denmark 1993–1997 418/394 
Dietary Vit E:  
4.30–14.8 mg/day 
Supplemental Vit E:  
0.94–78.23 mg/day 
Dietary Vit E:  
1.13 (0.61–2.10) 
Supplemental Vit E:  
1.00 (0.96–1.03) 
No 
association
[135] South  Korea 1999–2000 224/250 
Dietary Vit E:  
6.26–12.71 mg/day 
Dietary Vit E:  
0.71 (0.39–1.27) 
No 
association
a Pre-menopausal (Pre-M) or postmenopausal (Post-M) women. 
Previously, detailed assessments revealed that vitamin E (α-tocopherol) supplements did not protect 
against breast cancer [149,150]. Recently, Fulan et al. performed a meta-analysis on 38 studies 
between vitamin E and breast cancer [151]. For case-control studies, dietary vitamin E and total 
vitamin E reduced breast cancer risk by 18% and 11%, respectively [151]. When the cohort studies 
were pooled with the case-control studies, dietary vitamin E and total vitamin E both became 
nonsignificant [151]. Thus, a conclusion remains elusive between breast cancer and vitamin E. The 
term “vitamin E” is used loosely, and a distinction in these case-control and cohort studies need to 
clarify which variant of vitamin E is utilized.  
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Table 6. Cohort studies of vitamin E and breast cancer risk. 
Study Population  Year  Case/Control 
a Intake or blood levels 
Relative risk (95% CI) for 
highest vs. lowest level 
Conclusion
[136] Canada  1982–1987 519/1182  α-T: <3 vs. >7 mg/day  α-T: 1.05 (0.65–1.70) 
No 
association 
[137] Sweden  1987–1990  1271/59036 
Vit E: 9.3 vs. 3.8 mg/day 
(median) 
0.83 (0.6–1.14) 
No 
association 
[138]    
Pre-M: 
784/53938 
Vit E: 10 vs. 5 IU/day 
(median) 
0.81 (0.64–1.02) 
No 
association 
[139] Netherlands   
Post-M: 
650/62573 
Vit E: 19.8 vs. 6.9 mg/day 
(median) 
1.25 (0.85–1.85) 
No 
association 
[140] Finland    88/4697 
Vit E: levels were not 
specified 
1.08 
No 
association 
[141]  US  1986  570/21782  Vit E: 10 vs. 5 mg/day  0.81 (0.64–1.02) 
No 
association 
[142] US  1976–1982  1439/89494 
Dietary Vit E:  
<3.9 ~ ≥24.1 IU/day 
Supplemental Vit E:  
600 vs. 0 IU/day 
Dietary Vit E:  
0.90 (0.77–1.06) 
Supplemental Vit E:  
1.01 (0.69–0.49) 
No 
association 
[143] Canada    325/628 
Vit E: ~18 IU/day 
(median) 
1.32 (0.85–2.05) 
No 
association 
[144] US  1980–1987 
Post-M: 
344/18586 
Vit E: <4.3 ~ ≥9.3 mg/day 0.86 (0.61–1.21) 
No 
association 
[145]  Europe  1992–2000  7502/334493  Vit E: 5.4–19.5 mg/day  0.92 (0.77–1.11) 
No 
association 
[146] US  1993–1998  2879/81926 
Dietary Vit E:  
6.2–9.4 mg/day 
Supplemental Vit E:  
0–424 mg/day 
Dietary Vit E:  
1.03 (0.91–1.17) 
Supplemental Vit E:  
1.01 (0.90–1.14) 
No 
association 
[147] US  1991–1999 
Pre-M: 
714/90655 
Vit E: 7–59 mg/day 
Dietary Vit E:  
6–10 mg/day 
Vit E: 1.13 (0.89–1.43) 
Dietary Vit E:  
1.17 (0.92–1.50) 
No 
association 
a Pre-menopausal (Pre-M) or postmenopausal (Post-M) women. 
4.2. Intervention Studies 
The Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study examined the prevention 
of lung and other cancers with supplementation of all-racemic-α-tocopherol acetate (50 mg/day) and  
β-carotene (20 mg/day) daily, which did not have an effect on lung or colorectal cancer [152,153]. 
However, the ATBC study found that males supplemented with α-tocopherol acetate (50 mg daily) had 
32% lower prostate cancer incidence and 41% reduction in prostate cancer deaths [154]. The Physicians’ 
Health Study II gave supplements of 400 IU of α-tocopherol every other day or 500 mg of vitamin C 
daily and concluded that neither vitamin E nor C reduced the risk of prostate cancer [155]. The 
Selenium and Vitamin E Cancer Prevention Trial (SELECT) administered selenium (200 μg/day) and 
all rac-α-tocopheryl acetate (400 IU/day) and revealed that selenium or vitamin E, alone or in Nutrients 2011, 3  
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combination, did not prevent prostate cancer [156]. These previous clinical and epidemiological 
studies have been primarilyutilized α-tocopherol, and not a mixture of tocopherols or other variants of 
tocopherols for chemoprevention [37–40].  
There have been 3 breast cancer randomized controlled trials (RCT), which administered 
supplemental natural-source vitamin E (either 400 IU or 600 IU), and concluded that there was no 
overall benefit of vitamin E supplementation [37,157,158]. Only one RCT specified using the variant 
α-tocopherol [158], but in most cases, the studies do not identify which variant of vitamin E   
was utilized. Thus, epidemiological evidence between vitamin E and breast cancer is limited and 
inconsistent [41]. There are four tocopherols and four tocotrienols that comprise vitamin E, each which 
differ in chemical structure, bioavailability, and activity. Results will remain inconclusive unless the 
specific variant is identified for each study.  
5. Conclusion 
α-Tocopherol has been investigated over many years, while data are lacking for γ- and   
δ-tocopherols. A γ-enriched mixture of tocopherol is commonly found as a by-product of corn oil and 
should also be explored. The status of tocopherol as a chemopreventive agent remains unclear due to 
inconsistent results. In previous case-control and cohort studies, the term vitamin E may be vague, 
with few studies specifying which variant is utilized. A distinction needs to be addressed to determine 
the efficacy of each tocopherol variant and its chemopreventive activity. It has been suggested that  
γ-TmT, γ-tocopherol, and more recently δ-tocopherol may contribute to inhibiting tumor formation. 
Possible mechanism of actions in inhibiting breast cancer could be: inducing PPARγ expression and as 
a result reducing the expression of ERα, inducing Nrf2 which consequently reduces inflammation and 
oxidative stress, and inhibiting cell proliferation while inducing apoptosis. Further investigation is 
warranted with γ-TmT, γ- and δ-tocopherol in human prevention trials.  
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